A Study of Donanemab (LY3002813) in Healthy Chinese Participants

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The main purpose of this study is to evaluate the safety and tolerability of donanemab (LY3002813) when administered as single dose in healthy Chinese participants. The study will also assess how fast donanemab gets into the blood stream and how long it takes the body to remove it. The study is open to healthy participants. The study will last up to approximately 85 days.
Epistemonikos ID: ddf833a7acf09408ea46aab2cb0a797bb0b536bc
First added on: May 13, 2024